Asset Details
Do you wish to reserve the book?
Acquired thrombocytopenia and neutropenia after intrarenal BCG immunotherapy treatment for urothelial carcinoma of the kidney: a case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Acquired thrombocytopenia and neutropenia after intrarenal BCG immunotherapy treatment for urothelial carcinoma of the kidney: a case report
Do you wish to request the book?
Acquired thrombocytopenia and neutropenia after intrarenal BCG immunotherapy treatment for urothelial carcinoma of the kidney: a case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Acquired thrombocytopenia and neutropenia after intrarenal BCG immunotherapy treatment for urothelial carcinoma of the kidney: a case report
2025
Overview
BackgroundImmune cytopenias have been reported in the literature as a consequence of cancer immunotherapy. BCG has been used for urothelial carcinoma of the ureter and renal pelvis, either as treatment for carcinoma in situ or as adjuvant topical therapy to reduce recurrences.Case presentationHereby we describe the first reported case of combined immune thrombocytopenia and neutropenia as a consequence of BCG (Bacillus Calmette-Guérin) immunotherapy. In our case, the patient was a 65 year-old Caucasian male.ConclusionAfter exclusion of alternative diagnoses, most cases of BCG-induced immune cytopenias are successfully managed with blood and platelet transfusion support and discontinuation of BCG. Emergent situations (severe neutropenia or bleeding) call for treatment with immunosuppressive agents. This case report helps provide guidance on how to recognize and manage a patient with immune cytopenia as a consequence of BCG immunotherapy.
